中晚期食管癌患者经艾迪注射液联合放化疗治疗的临床疗效研究  

The clinical effect of Addie injection combined with radiotherapy and chemotherapy in the treatment of patients with advanced esophageal cancer

作　　者：刘贤称[1] 姚宁华[1] 钱静[1] 陈不尤[1] 季斌[1] 

机构地区：[1]南通大学附属医院放疗科,江苏南通226000

出　　处：《临床与病理杂志》2016年第10期1498-1501,共4页Journal of Clinical and Pathological Research

摘　　要：目的:研究分析中晚期食管癌患者经艾迪注射液联合放化疗治疗的临床疗效。方法:选取在我院治疗的中晚期食管癌患者92例(2013年9月到2015年9月)。将其动态随机化分2组,研究组和对照组各46例。对照组患者给予同步放化疗治疗,研究组患者在同步放化疗的基础上联合使用艾迪注射液治疗,对比两组患者的临床疗效、生活质量与免疫变化情况。结果:研究组患者的总缓解率为80.43%、提高稳定率达到了76.09%,治疗后CD3+T细胞76.16%±6.61%、CD4+T细胞35.71%±4.33%、CD8+T细胞36.27%±9.13%,与对照组比较均有明显优势,P<0.05。结论:采用艾迪注射液与放化疗结合的方式对中晚期食管癌患者进行治疗的效果显著,可以广泛应用于临床上。Objective：To study the clinical effect of Addie injection combined with radiotherapy and chemotherapy in patients with advanced esophageal cancer. Methods：92 cases of middle and advanced esophageal cancer patients treated in our hospital were selected and divided into 2 groups, randomly （n=46, respectively）. The control group was treated with radiotherapy and chemotherapy, while the experimental group was given Addie injection combined with radiotherapy and chemotherapy. Clinical effcacy, life quality and T lymphocytes percentage were compared between the two groups. Results：hTe total remission rate （80.43%）, the improvement rate of quality of life （76.09%）, CD3＋（76.16%±6.61%）, CD4^＋（35.71%±4.33%）, CD8^＋（36.27%±9.13%） in the study group were significantly better than those in the control group, and the P value was less than 0.05. Conclusion：The effect of Addie injection combined with radiotherapy and chemotherapy in the treatment of middle and advanced esophageal cancer patients is obvious.

关 键 词：艾迪注射液 放化疗 中晚期食管癌 临床疗效 

分 类 号：R735.1[医药卫生—肿瘤]